These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 29228203)

  • 1. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
    Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
    Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Wilson J; Yarnall AJ; Craig CE; Galna B; Lord S; Morris R; Lawson RA; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Ray NJ; Rochester L
    Mov Disord; 2021 Mar; 36(3):611-621. PubMed ID: 33382126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
    Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
    Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.
    Ray NJ; Lawson RA; Martin SL; Sigurdsson HP; Wilson J; Galna B; Lord S; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Rea RC; Bergamino M; Rochester L; Yarnall AJ
    Brain; 2023 Mar; 146(3):1053-1064. PubMed ID: 35485491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease.
    Schulz J; Pagano G; Fernández Bonfante JA; Wilson H; Politis M
    Brain; 2018 May; 141(5):1501-1516. PubMed ID: 29701787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline.
    Labrador-Espinosa MA; Silva-Rodríguez J; Reina-Castillo MI; Mir P; Grothe MJ
    Mov Disord; 2023 Oct; 38(10):1871-1880. PubMed ID: 37492892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease.
    Berlot R; Pirtošek Z; Brezovar S; Koritnik B; Teipel SJ; Grothe MJ; Ray NJ
    Brain Imaging Behav; 2022 Feb; 16(1):118-129. PubMed ID: 34176042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease.
    Ray NJ; Kanel P; Bohnen NI
    Ann Neurol; 2023 May; 93(5):991-998. PubMed ID: 36597786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson's disease.
    Crowley SJ; Kanel P; Roytman S; Bohnen NI; Hampstead BM
    Brain; 2024 May; 147(5):1799-1808. PubMed ID: 38109781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment.
    Rea RC; Berlot R; Martin SL; Craig CE; Holmes PS; Wright DJ; Bon J; Pirtošek Z; Ray NJ
    Neurobiol Aging; 2021 Oct; 106():37-44. PubMed ID: 34233212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
    Grothe MJ; Labrador-Espinosa MA; Jesús S; Macías-García D; Adarmes-Gómez A; Carrillo F; Camacho EI; Franco-Rosado P; Lora FR; Martín-Rodríguez JF; Barberá MA; Pastor P; Arroyo SE; Vila BS; Foraster AC; Martínez JR; Padilla FC; Morlans MP; Aramburu IG; Ceberio JI; Vara JH; de Fábregues-Boixar O; de Deus Fonticoba T; Pascual-Sedano B; ; Kulisevsky J; Martínez-Martín P; Santos-García D; Mir P
    Parkinsonism Relat Disord; 2021 Jul; 88():68-75. PubMed ID: 34144230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease.
    Barrett MJ; Murphy JM; Zhang J; Blair JC; Flanigan JL; Nawaz H; Dalrymple WA; Sperling SA; Patrie J; Druzgal TJ
    Parkinsonism Relat Disord; 2021 Sep; 90():27-32. PubMed ID: 34348192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease.
    Gratwicke JP; Foltynie T
    Brain; 2018 Jan; 141(1):7-10. PubMed ID: 29325047
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Gang M; Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Hasegawa T; Aoki M; Takeda A; Mori E; Suzuki K
    Mov Disord; 2020 May; 35(5):825-832. PubMed ID: 31971293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD).
    Scheef L; Grothe MJ; Koppara A; Daamen M; Boecker H; Biersack H; Schild HH; Wagner M; Teipel S; Jessen F
    Neuroimage Clin; 2019; 21():101612. PubMed ID: 30555006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study.
    Teipel SJ; Meindl T; Grinberg L; Grothe M; Cantero JL; Reiser MF; Möller HJ; Heinsen H; Hampel H
    Hum Brain Mapp; 2011 Sep; 32(9):1349-62. PubMed ID: 20672311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease.
    Björklund A; Barker RA
    Brain; 2024 Jun; 147(6):1937-1952. PubMed ID: 38279949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.